drugset
drugset / Trial / NCT03434977

A Phase 1 Food Effect Study of Azilsartan (TAK-536) Pediatric Formulation

NCT03434977 ↗

Phase 1 Completed 12 enrolled Takeda
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the PK of TAK-536 and effect of food on the PK following single oral administration of TAK-536 pediatric formulation in Japanese healthy adult male participants.

Timeline

Start
2018-02-14
Primary completion
2018-03-11
Completion
2018-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 10 mg Oral

Indications

No indication recorded.